Are we underestimating the leukemogenic risk of hydroxyurea

Saudi Medical Journal

Volumn 23, Issue 11, 2002, Pages 1411-1413

  Al Jam'a, Ali H ^a   Al Dabbous, Ibrahim A ^a   Al Khatti, Adil A ^b   Esan, Folayan G ^a  

^a QATIF CENTRAL HOSPITAL   (Saudi Arabia)

^b DHAHRAN HEALTH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; HYDROXYUREA; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLOOD DISEASE; BONE MARROW BIOPSY; CANCER RISK; CASE REPORT; FEMALE; HEADACHE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; LIVER TOXICITY; LONG TERM CARE; MYELOPROLIFERATIVE DISORDER; SICKLE CELL ANEMIA; SOLID TUMOR; THROMBOCYTOPENIA;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOID, ACUTE;

EID: 0036873018     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995; 332: 1317-1322.
2. Drugs Facts and Comparison Group. Drug Facts and Comparisons. 53rd ed. St Louis (MO): A. Wolters Kluwer Company; 1999. p. 3534-3535.
3. Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 1994; 52: 134-139.
4. Najean Y, Rain JD. Treatment of polycythemia vera: Use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997; 89: 2319-2327.
5. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 1998; 91: 616-622.
6. Rauch A, Borromeo M, Ghafoor A, Khoyratty B, Maheshwari J. Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia [Abstract]. Blood 1999; 94 Suppl 1: 415a.
7. Scott W. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Int Med 2000; 133: 925-926.
8. Giles FJ, Koeffler HP. Secondary myelodysplastic syndromes and leukemias. Curr Opin Hematol 1994; 1: 256-260.
9. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with In vivo hydroxyurea exposure. Blood 2000; 95: 3589-3593.
10. Quesnal B, Kantarjian H, Bjargaard JP, Brault P, Estey E, Lai JL et al. Therapy-related acute myeloid leukemia with t (8;21), inv (16) and t (8,16). A report on 25 cases and review of the literature. J Clin Oncol 1993; 11: 2370-2379.
11. Triadou P, Maier-Redelsperger M, Krishnamoorty R, Deschamps A, Casadevall N, Dunda O et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv Rev Fr Hematol 1994; 36: 367-372.
12. Steinberg MH, Barton F, Castro O, Koshy M, Eckman J, Terrin M. Risks and benefits of hydroxyurea (HU) in adult sickle cell anemia: effects at 6-7years [Abstract]. Blood 1999; 94: 644a.